In:
Hematological Oncology, Wiley, Vol. 39, No. 4 ( 2021-10), p. 490-497
Abstract:
This study aimed to identify the prognostic factors in patients with Waldeyer's ring diffuse large B‐cell lymphoma (WR‐DLBCL), comparing the efficacy of radiotherapy (RT) for the WR‐DLBCL patients in the pre‐rituximab and rituximab eras. We conducted a retrospective analysis of 134 patients diagnosed with WR‐DLBCL. Univariate and multivariate analyses were performed to identify the prognostic factors for WR‐DLBCL. Then, we divided these patients into the rituximab plus chemotherapy group (R‐chemotherapy) ( n = 88) and chemotherapy group ( n = 46), and the Kaplan–Meier and Cox regression model analyses were applied to investigate the treatment value of RT in both the groups. Multivariate analysis revealed international prognostic index (IPI) ≥ 3 and chemotherapy without rituximab as significant risk factors for the progression‐free survival (PFS, IPI ≥ 3: p = 0.001; chemotherapy without rituximab: p = 0.002) and overall survival (OS, IPI ≥ 3, p 〈 0.001; chemotherapy without rituximab, p = 0.024). Rituximab combined with chemotherapy significantly improved PFS ( p = 0.002) and OS ( p = 0.006) in these patients. RT did not significantly contribute to the survival in the overall cohort analysis, whereas in the subgroup analysis, RT significantly improved the PFS ( p = 0.025) and OS ( p = 0.029) for the patients in the chemotherapy group, but not in the R‐chemotherapy group. In conclusion, the WR‐DLBCL patients could benefit from RT in the pre‐rituximab era, whereas the addition of rituximab to chemotherapy significantly improved the survival of WR‐DLBCL patients, and the clinical benefit of RT was reduced.
Type of Medium:
Online Resource
ISSN:
0278-0232
,
1099-1069
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2001443-0
Permalink